- Home
- MOS vs BMRN Comparison
MOS vs BMRN Comparison
Compare MOS & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOS
- BMRN
- Stock Information
- Founded
- MOS 1987
- BMRN 1996
- Country
- MOS United States
- BMRN United States
- Employees
- MOS N/A
- BMRN N/A
- Industry
- MOS Agricultural Chemicals
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- MOS Industrials
- BMRN Health Care
- Exchange
- MOS Nasdaq
- BMRN Nasdaq
- Market Cap
- MOS 10.2B
- BMRN 11.3B
- IPO Year
- MOS 2004
- BMRN 1999
- Fundamental
- Price
- MOS $32.47
- BMRN $57.54
- Analyst Decision
- MOS Buy
- BMRN Buy
- Analyst Count
- MOS 12
- BMRN 23
- Target Price
- MOS $36.67
- BMRN $93.14
- AVG Volume (30 Days)
- MOS 5.3M
- BMRN 2.5M
- Earning Date
- MOS 08-05-2025
- BMRN 08-04-2025
- Dividend Yield
- MOS 2.71%
- BMRN N/A
- EPS Growth
- MOS 292.19
- BMRN 154.69
- EPS
- MOS 2.95
- BMRN 3.40
- Revenue
- MOS $11,253,400,000.00
- BMRN $3,063,608,000.00
- Revenue This Year
- MOS $18.68
- BMRN $12.34
- Revenue Next Year
- MOS N/A
- BMRN $10.01
- P/E Ratio
- MOS $11.00
- BMRN $16.93
- Revenue Growth
- MOS N/A
- BMRN 18.36
- 52 Week Low
- MOS $22.36
- BMRN $52.93
- 52 Week High
- MOS $38.23
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- MOS 40.55
- BMRN 47.03
- Support Level
- MOS $31.13
- BMRN $56.45
- Resistance Level
- MOS $32.65
- BMRN $58.62
- Average True Range (ATR)
- MOS 0.97
- BMRN 1.95
- MACD
- MOS -0.29
- BMRN -0.25
- Stochastic Oscillator
- MOS 33.98
- BMRN 15.51
About MOS Mosaic Company (The)
Mosaic is one of the largest phosphate and potash producers in the world. The company's assets include phosphate rock mines in Florida, Brazil, and Peru and potash mines in Saskatchewan, New Mexico, and Brazil. Mosaic also runs a large fertilizer distribution operation in Brazil through its Mosaic Fertilizantes business.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.